SSA
TCRX icon

Schonfeld Strategic Advisors’s TScan Therapeutics TCRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22,200
Closed -$185K – 2529
2021
Q3 		$185K Buy
+22,200
New +$206K ﹤0.01% 1797

Other funds holding TCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Schonfeld Strategic Advisors's TCRX Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of TScan Therapeutics (TCRX) in Q4 2021, closing a stake of 22,200 shares — an estimated $185K sold.

Schonfeld Strategic Advisors first reported a position in TCRX in Q3 2021 and held it in 1 quarter. The position peaked at $185K in Q3 2021. 29 funds tracked by Wall St. Rank hold TCRX as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining TScan Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 22,200 TScan Therapeutics shares in Q4 2021, an estimated $185K.
  • Schonfeld Strategic Advisors first reported a position in TScan Therapeutics in Q3 2021 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's TScan Therapeutics position peaked at $185K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.